Modulating Gene Expression
We are pioneering medical research by developing innovative therapeutics with new modes of action. Cellestia is developing first-in-class therapies to control pathogenic gene expression by selective inhibition of previously undruggable transcription factors in the cell nucleus.
The company’s clinical lead, CB-103, has advanced to phase 2 in oncology, followed by a rich R&D pipeline of novel gene transcription factor inhibitors in oncology, auto-immune and inflammatory disorders.
